Supplementary Data

Supersaturated silica-lipid hybrid (super-SLH) oral drug delivery systems: Balancing drug loading and in vivo performance

Hayley B. Schultz, Miia Kovalainen, Karl F. Peressin, Nicky Thomas and Clive A. Prestidge

University of South Australia, School of Pharmacy and Medical Science, Adelaide, South Australia 5000, Australia

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes, South Australia 5095, Australia

University of Oulu, Research Unit of Biomedicine, 90014 Oulu University, Finland

Supplemental Figure 1: PK profiles of IBU formulations orally administered to Sprague-Dawley rats at a dose of 10 mg/kg over 24 h (mean ± SE, n=4 or 5 (Nurofen)).

Supplemental Table 1: The IBU formulations AUCs for *in vitro* dissolution and *in vivo* PK studies (mean ± SE, n=4 or 5 (Nurofen)).

	Nurofen	Spray-dried SLH	Super-SLH A	Super-SLH B	Super-SLH C
***In vitro* AUC$_{0-1h}$ (μg/mL.h)**	19.8 ± 1.0	38.8 ± 0.6	26.5 ± 0.8	25.4 ± 0.8	16.9 ± 1.9
***In vivo* AUC$_{0-10h}$ (μg/mL.h)**	21.1 ± 2.5	48.0 ± 5.1	47.1 ± 7.1	47.0 ± 5.3	19.3 ± 2.3